188 related articles for article (PubMed ID: 19443905)
1. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.
LaPensee EW; Schwemberger SJ; LaPensee CR; Bahassi el M; Afton SE; Ben-Jonathan N
Carcinogenesis; 2009 Aug; 30(8):1298-304. PubMed ID: 19443905
[TBL] [Abstract][Full Text] [Related]
2. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy.
LaPensee EW; Ben-Jonathan N
Endocr Relat Cancer; 2010 Jun; 17(2):R91-107. PubMed ID: 20071456
[TBL] [Abstract][Full Text] [Related]
3. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
6. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi.
Goto S; Ihara Y; Urata Y; Izumi S; Abe K; Koji T; Kondo T
FASEB J; 2001 Dec; 15(14):2702-14. PubMed ID: 11726546
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial DNA depletion promotes impaired oxidative status and adaptive resistance to apoptosis in T47D breast cancer cells.
Yu M; Shi Y; Wei X; Yang Y; Zang F; Niu R
Eur J Cancer Prev; 2009 Nov; 18(6):445-57. PubMed ID: 19609211
[TBL] [Abstract][Full Text] [Related]
10. NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress.
Clark DW; Mitra A; Fillmore RA; Jiang WG; Samant RS; Fodstad O; Shevde LA
Curr Cancer Drug Targets; 2008 Aug; 8(5):421-30. PubMed ID: 18690848
[TBL] [Abstract][Full Text] [Related]
11. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.
Doherty B; Lawlor D; Gillet JP; Gottesman M; O'Leary JJ; Stordal B
Anticancer Res; 2014 Jan; 34(1):503-7. PubMed ID: 24403508
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells.
Luker KE; Pica CM; Schreiber RD; Piwnica-Worms D
Cancer Res; 2001 Sep; 61(17):6540-7. PubMed ID: 11522652
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells.
Townsend DM; Shen H; Staros AL; Gaté L; Tew KD
Mol Cancer Ther; 2002 Oct; 1(12):1089-95. PubMed ID: 12481432
[TBL] [Abstract][Full Text] [Related]
15. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
17. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
18. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
Zou M; Hu X; Xu B; Tong T; Jing Y; Xi L; Zhou W; Lu J; Wang X; Yang X; Liao F
Oncol Rep; 2019 Feb; 41(2):989-998. PubMed ID: 30431119
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
